Stephen Livesey
Director/Miembro de la Junta en Carina Biotech Pty Ltd. .
Cargos activos de Stephen Livesey
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Director/Miembro de la Junta | - | - |
Historial de carrera de Stephen Livesey
Estadísticas
Internacional
Australia | 2 |
Operativa
Director/Board Member | 1 |
Sectorial
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Health Technology |
- Bolsa de valores
- Insiders
- Stephen Livesey
- Experiencia